皓宸医疗(002622) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥129,643,591.18, representing a 57.17% increase compared to ¥82,485,669.07 in the same period last year[4] - The net loss attributable to shareholders was ¥707,071.25, a 97.21% improvement from a net loss of ¥25,339,030.73 in the previous year[4] - The net cash flow from operating activities was ¥3,397,477.87, a significant turnaround from a negative cash flow of ¥32,253,006.95 in the same period last year, marking a 110.53% increase[4] - The company reported a net loss of CNY 228,901,186.14 for Q1 2023, compared to a loss of CNY 228,194,114.89 in the previous year[13] - The net profit for Q1 2023 was a loss of CNY 3,150,084.93, an improvement from a loss of CNY 36,395,477.46 in the same period last year[16] - The operating profit for Q1 2023 was a loss of CNY 3,105,393.10, significantly better than the loss of CNY 36,949,175.55 in Q1 2022[16] - The total comprehensive income for Q1 2023 was a loss of CNY 3,182,717.04, compared to a loss of CNY 36,704,772.00 in Q1 2022[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,672,547,396.21, reflecting a 1.21% increase from ¥1,652,618,278.43 at the end of the previous year[4] - Cash and cash equivalents at the end of Q1 2023 were CNY 151,850,814.49, an increase from CNY 120,113,833.90 at the beginning of the year[11] - Total assets as of March 31, 2023, were CNY 1,672,547,396.21, compared to CNY 1,635,408,931.74 at the beginning of the year[13] - Total liabilities increased to CNY 1,106,976,510.32 from CNY 1,066,655,328.80 at the start of the year[13] - The company's equity attributable to shareholders was CNY 571,761,045.51, a slight decrease from CNY 572,500,748.87 at the beginning of the year[13] Cash Flow and Management - The cash received from sales of goods and services increased by 52.5%, totaling an increase of ¥46,340,000 compared to the previous year[6] - The company received tax refunds amounting to CNY 1,355,460.09 in Q1 2023, compared to CNY 807,080.32 in Q1 2022, indicating better cash flow management[19] - The company incurred financial expenses of CNY 8,273,195.31 in Q1 2023, down from CNY 11,223,616.88 in Q1 2022, reflecting improved cost management[16] Research and Development - The company reported a decrease in research and development expenses by 51.77%, amounting to a reduction of ¥720,000 compared to the previous year[6] - Research and development expenses decreased to CNY 669,850.77 in Q1 2023 from CNY 1,388,879.00 in Q1 2022, indicating a reduction in R&D investment[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 51,221, with no preferred shareholders[8] - The company's basic earnings per share improved by 97.35%, reaching -¥0.0008 compared to -¥0.0302 in the same period last year[4] - The basic and diluted earnings per share for Q1 2023 were both -0.0008, an improvement from -0.0302 in Q1 2022[16] Future Plans - The company plans to focus on expanding its market presence and developing new technologies in the upcoming quarters[12]